Market Place
Sourcing Support
Cybin`s psychedelic drug reduces 12-month symptom severity
19 Nov 2024 //
FIERCE BIOTECH
Cybin to Present 12-Month Phase 2 Data for CYB003 in MDD
14 Nov 2024 //
BUSINESSWIRE
Cybin Initiates Phase 3 PARADIGM Trial for CYB003 in Depression
13 Nov 2024 //
BUSINESSWIRE
Cybin Grants First U.S. Patent For CYB005 Phenethylamines Program
24 Oct 2024 //
BUSINESSWIRE
Cybin to Participate in Water Tower Research Chat on Oct 8, 2024
03 Oct 2024 //
BUSINESSWIRE
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
01 Oct 2024 //
BUSINESSWIRE
Cybin to Attend TD Cowen Neuropsychiatry Summit
24 Sep 2024 //
BUSINESSWIRE
Cybin Provides Corporate Update on Upcoming Clinical Milestones
19 Sep 2024 //
BUSINESSWIRE
Cybin Reports Q1 FY2025 Results And Business Highlights
08 Aug 2024 //
BUSINESSWIRE
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
07 Aug 2024 //
BUSINESSWIRE
Naropa University Announces Psilocybin Facilitator Training Certificate
30 Jul 2024 //
BUSINESSWIRE
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
26 Jun 2024 //
BUSINESSWIRE
Cybin To Join H.C. Wainwright Neuro Perspectives Conference
19 Jun 2024 //
BUSINESSWIRE
Cybin Appoints Dr Atul Mahableshwarkar As SVP Clinical Development
11 Jun 2024 //
BUSINESSWIRE
Cybin At Psychedelic Research Conferences In June 2024
29 May 2024 //
BUSINESSWIRE
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
14 May 2024 //
BUSINESSWIRE
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
06 May 2024 //
BUSINESSWIRE
Cybin to Participate at the 27th Annual Milken Institute Global Conference
25 Apr 2024 //
BUSINESSWIRE
Cybin Publishes Research On Psychedelic Compounds In J. Medicinal Chemistry
18 Apr 2024 //
BUSINESSWIRE
Cybin Granted US Patent For CYB003 MDD Program
16 Apr 2024 //
BUSINESSWIRE
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10 Apr 2024 //
BUSINESSWIRE
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 M
19 Mar 2024 //
BUSINESSWIRE
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
18 Mar 2024 //
BUSINESSWIRE
Cybin Initiates Phase 2 Study of CYB004 in Generalized Anxiety Disorder
15 Mar 2024 //
BUSINESSWIRE
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003
14 Mar 2024 //
BUSINESSWIRE
Cybin Receives Breakthrough Therapy Designation for Psychedelic Molecule CYB003
13 Mar 2024 //
BUSINESSWIRE
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
27 Feb 2024 //
BUSINESSWIRE
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
14 Feb 2024 //
BUSINESSWIRE
Cybin Announces Grant of Two Patents in Japan in Support of its DMT Program
07 Feb 2024 //
BUSINESSWIRE
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004
23 Jan 2024 //
BUSINESSWIRE
Cybin Announces Positive Data from Phase 1 Studies of CYB004 and SPL028
08 Jan 2024 //
BUSINESSWIRE
Cybin Highlights Recent Topline Results Across Development Programs
04 Jan 2024 //
BUSINESSWIRE
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003
06 Dec 2023 //
BUSINESSWIRE
Cybin Announces Four Poster Presentations at the 2023 Annual Meeting
05 Dec 2023 //
BUSINESSWIRE
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003
30 Nov 2023 //
BUSINESSWIRE
Investors unenthused by Cybin`s latest ph. 2 depression data
30 Nov 2023 //
FIERCE BIOTECH
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing
20 Nov 2023 //
BUSINESSWIRE
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003
16 Nov 2023 //
BUSINESSWIRE
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
15 Nov 2023 //
BUSINESSWIRE
Cybin Announces Closing of Offering of Units Led by Institutional Shareholders
14 Nov 2023 //
BUSINESSWIRE
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
14 Nov 2023 //
BUSINESSWIRE
Cybin Announces up to US$64 Million Offering of Units
10 Nov 2023 //
BUSINESSWIRE
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
03 Nov 2023 //
BUSINESSWIRE
Cybin Provides Corporate Update
01 Nov 2023 //
BUSINESSWIRE
Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003
31 Oct 2023 //
PR NEWSWIRE
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003
31 Oct 2023 //
BUSINESSWIRE
Cybin Announces Grant of EU Patent Protecting Proprietary Deuterated Programs
26 Oct 2023 //
BUSINESSWIRE
Cybin Announces Grant of Two New United States Patents Protecting DMT Program
25 Oct 2023 //
BUSINESSWIRE
Cybin Completes Acquisition of Small Pharma Inc.
23 Oct 2023 //
BUSINESSWIRE
Cybin Announces Results of Annual and Special Meeting of Shareholders
12 Oct 2023 //
BUSINESSWIRE
Cybin to Present an Abstract and Moderate a Psychedelic Workshop
06 Oct 2023 //
BUSINESSWIRE
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
04 Oct 2023 //
BUSINESSWIRE
Cybin Completes Dosing in Phase 2 Study of CYB003
03 Oct 2023 //
BUSINESSWIRE
Cybin Announces Agreement with Fluence to Support Training for CYB003 Trial
26 Sep 2023 //
BUSINESSWIRE
Cybin to Participate in the Cantor Global Healthcare Conference
25 Sep 2023 //
BUSINESSWIRE
Cybin Completes Enrollment in Ph 2 Study of CYB003 in Major Depressive Disorder
21 Sep 2023 //
BUSINESSWIRE
Cybin Announces Date of Annual and Special Meeting of Shareholders
21 Sep 2023 //
BUSINESSWIRE
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
05 Sep 2023 //
BUSINESSWIRE
Cybin to Acquire Small Pharma Inc.
28 Aug 2023 //
BUSINESSWIRE
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
23 Aug 2023 //
BUSINESSWIRE
